R P DeMatteo

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. ncbi Genome wide analysis and clinical correlation of chromosomal and transcriptional mutations in cancers of the biliary tract
    George Miller
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Exp Clin Cancer Res 28:62. 2009
  2. ncbi Recent advances in hepatic resection
    R P DeMatteo
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Semin Surg Oncol 19:200-7. 2000
  3. ncbi Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST)
    Ronald P Dematteo
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 112:608-15. 2008
  4. ncbi Results of tyrosine kinase inhibitor therapy followed by surgical resection for metastatic gastrointestinal stromal tumor
    Ronald P Dematteo
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Ann Surg 245:347-52. 2007
  5. ncbi The GIST of targeted cancer therapy: a tumor (gastrointestinal stromal tumor), a mutated gene (c-kit), and a molecular inhibitor (STI571)
    Ronald P Dematteo
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Ann Surg Oncol 9:831-9. 2002
  6. ncbi Management of primary liver sarcomas
    Juürgen Weitz
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Cancer 109:1391-6. 2007
  7. ncbi Treatment of advanced gastrointestinal stromal tumor: a marriage of targeted therapy and surgery?
    Ronald P Dematteo
    Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY, 10021, USA
    Ann Surg Oncol 14:1-2. 2007
  8. ncbi A little teaching point for the fellows
    Ronald P Dematteo
    Hepatobiliary Service, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
    Surgery 138:959-60. 2005
  9. ncbi Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma
    W R Jarnagin
    Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Ann Surg 234:507-17; discussion 517-9. 2001
  10. ncbi A clinical scoring system predicts the yield of diagnostic laparoscopy in patients with potentially resectable hepatic colorectal metastases
    W R Jarnagin
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 91:1121-8. 2001

Research Grants

  1. STI571 Therapy for Gastrointestinal Stromal Tumors
    Ronald DeMatteo; Fiscal Year: 2002
  2. Liver Dendritic Cells in Tolerance and Immunity
    Ronald DeMatteo; Fiscal Year: 2007
  3. Molecular Mechanisms in Gastrointestinal Stromal Tumor
    Ronald DeMatteo; Fiscal Year: 2007
  4. Natural Killer Dendritic Cells in Listeria Infection
    Ronald DeMatteo; Fiscal Year: 2007
  5. Liver Dendritic Cells in Tolerance and Immunity
    Ronald P Dematteo; Fiscal Year: 2010

Detail Information

Publications93

  1. ncbi Genome wide analysis and clinical correlation of chromosomal and transcriptional mutations in cancers of the biliary tract
    George Miller
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Exp Clin Cancer Res 28:62. 2009
    ..The pathogenesis of biliary cancers is ill-defined. This study investigates changes in gene expression and copy number in biliary cancers and correlates these changes with anatomical site of origin, histopathology and outcome...
  2. ncbi Recent advances in hepatic resection
    R P DeMatteo
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Semin Surg Oncol 19:200-7. 2000
    ..We present a summary of our experience with these advances...
  3. ncbi Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST)
    Ronald P Dematteo
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 112:608-15. 2008
    ..Although the efficacy of tyrosine kinase inhibitors in metastatic GIST depends on tumor mutation status, there have been conflicting reports on the prognostic importance of KIT mutation in primary GIST...
  4. ncbi Results of tyrosine kinase inhibitor therapy followed by surgical resection for metastatic gastrointestinal stromal tumor
    Ronald P Dematteo
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Ann Surg 245:347-52. 2007
    ..Nearly all tumors have an activating mutation in the KIT or, less often, PDGFRalpha, gene. Therapy with tyrosine kinase inhibitors benefits over 80% of patients with advanced GIST, but most patients eventually develop drug resistance...
  5. ncbi The GIST of targeted cancer therapy: a tumor (gastrointestinal stromal tumor), a mutated gene (c-kit), and a molecular inhibitor (STI571)
    Ronald P Dematteo
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Ann Surg Oncol 9:831-9. 2002
    ..Although STI571 was first applied to GIST only 2 years ago, it has already revolutionized the treatment of patients with metastatic disease and is also currently being tested as an adjuvant therapy after the resection of primary GIST...
  6. ncbi Management of primary liver sarcomas
    Juürgen Weitz
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Cancer 109:1391-6. 2007
    ..Primary hepatic sarcoma is a rare entity. The objectives of the study were to define treatment and long-term outcome and to identify prognostic factors...
  7. ncbi Treatment of advanced gastrointestinal stromal tumor: a marriage of targeted therapy and surgery?
    Ronald P Dematteo
    Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY, 10021, USA
    Ann Surg Oncol 14:1-2. 2007
  8. ncbi A little teaching point for the fellows
    Ronald P Dematteo
    Hepatobiliary Service, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
    Surgery 138:959-60. 2005
  9. ncbi Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma
    W R Jarnagin
    Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Ann Surg 234:507-17; discussion 517-9. 2001
    ..To analyze resectability and survival in patients with hilar cholangiocarcinoma according to a proposed preoperative staging scheme that fully integrates local, tumor-related factors...
  10. ncbi A clinical scoring system predicts the yield of diagnostic laparoscopy in patients with potentially resectable hepatic colorectal metastases
    W R Jarnagin
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 91:1121-8. 2001
    ....
  11. ncbi Gastrointestinal stromal tumors in children and young adults: a clinicopathologic, molecular, and genomic study of 15 cases and review of the literature
    Sonam Prakash
    Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA
    J Pediatr Hematol Oncol 27:179-87. 2005
    ..The distinct gene expression profile suggests avenues for investigation of pathogenesis and potential therapeutic strategies...
  12. ncbi Downstaging in pancreatic cancer: a matched analysis of patients resected following systemic treatment of initially locally unresectable disease
    K A Bickenbach
    Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY, USA
    Ann Surg Oncol 19:1663-9. 2012
    ..The objective of this study was to evaluate outcome of initially unresectable patients who respond to multimodality therapy and undergo resection...
  13. ncbi Caudate hepatectomy for cancer: a single institution experience with 150 patients
    William G Hawkins
    Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
    J Am Coll Surg 200:345-52. 2005
    ..Although caudate resection of the liver can be performed safely, concomitant major vascular reconstruction substantially increases the mortality of the procedure...
  14. ncbi Pathologic and molecular heterogeneity in imatinib-stable or imatinib-responsive gastrointestinal stromal tumors
    Narasimhan P Agaram
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Clin Cancer Res 13:170-81. 2007
    ..Our goal was to investigate the spectrum of pathologic response and molecular alterations in a group of GIST patients, clinically defined as having imatinib-stable/imatinib-responsive lesions, who underwent surgical resection...
  15. ncbi Intrahepatic cholangiocarcinoma: resectability, recurrence pattern, and outcomes
    S M Weber
    Hepatobiliary Service, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
    J Am Coll Surg 193:384-91. 2001
    ..Although complete resection improved survival, recurrence was common. The majority of recurrences were local or regional, which may help guide future adjuvant therapy strategies...
  16. ncbi Results of hepatic resection for sarcoma metastatic to liver
    R P DeMatteo
    Department of Surgery, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Ann Surg 234:540-7; discussion 547-8. 2001
    ..Hepatectomy should be considered when complete gross resection is possible, especially when the time to the development of liver metastasis exceeds 2 years...
  17. ncbi Operative blood loss independently predicts recurrence and survival after resection of hepatocellular carcinoma
    Steven C Katz
    Hepatopancreatobiliary Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Ann Surg 249:617-23. 2009
    ..To determine if the degree of blood loss during resection of hepatocellular carcinoma (HCC) is predictive of recurrence and long-term survival...
  18. ncbi Perihepatic lymph node assessment in patients undergoing partial hepatectomy for malignancy
    Stephen R Grobmyer
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Ann Surg 244:260-4. 2006
    ..Routine sampling of perihepatic lymph nodes will therefore have a low yield in patients without some evidence of disease on preoperative CT or PET scans or at the time of exploration...
  19. ncbi Outcome after hepatectomy for multiple (four or more) colorectal metastases in the era of effective chemotherapy
    Peter Kornprat
    Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, New York 10021, USA
    Ann Surg Oncol 14:1151-60. 2007
    ..Despite an unknown benefit, hepatic resection is playing an increasing role in patients with extensive disease...
  20. ncbi Clinical management of gastrointestinal stromal tumors: before and after STI-571
    Ronald P Dematteo
    Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
    Hum Pathol 33:466-77. 2002
    ..The advent of STI-571 has markedly altered the clinical approach to GIST. It has proven to be effective in metastatic GIST and is also under investigation as a neoadjuvant and adjuvant therapy...
  21. ncbi The role of adjuvant therapy after liver resection for colorectal cancer metastases
    L Ruo
    Department of Surgery, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Clin Colorectal Cancer 1:154-66; discussion 167-8. 2001
    ..Identification of subgroups through clinical features, molecular markers, proteins, or specific tumor properties may also help to individualize treatment...
  22. ncbi Clinical significance of intraoperative bile duct margin assessment for hilar cholangiocarcinoma
    Itaru Endo
    Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Ann Surg Oncol 15:2104-12. 2008
    ..Frozen section analysis of bile duct margins is often used to guide the extent of surgical resection for hilar cholangiocarcinoma (HCCA), but the usefulness of this practice is unknown...
  23. ncbi What is the yield of intraoperative ultrasonography during partial hepatectomy for malignant disease?
    W R Jarnagin
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Am Coll Surg 192:577-83. 2001
    ..This study was undertaken to reassess the yield of IOUS in light of recent improvements in preoperative staging...
  24. ncbi 18F-fluorodeoxyglucose positron emission tomography influences management decisions in patients with biliary cancer
    Carlos U Corvera
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Am Coll Surg 206:57-65. 2008
    ..The role of PET in detecting disease recurrence after resection was also examined...
  25. ncbi Combined surgical and molecular therapy: the gastrointestinal stromal tumor model
    Jason S Gold
    Hepatobiliary Service, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
    Ann Surg 244:176-84. 2006
    ..CONCLUSIONS: The treatment paradigm for GIST has required the integration of surgery and molecular therapy and this will likely serve as a paradigm for the treatment of other solid tumors as targeted agents are developed...
  26. ncbi Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors
    Narasimhan P Agaram
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Genes Chromosomes Cancer 47:853-9. 2008
    ..A secondary V600E BRAF mutation could represent an alternative mechanism of imatinib resistance. Kinase inhibitors targeting BRAF may be effective therapeutic options in this molecular GIST subset...
  27. ncbi Targeted molecular therapy for cancer: the application of STI571 to gastrointestinal stromal tumor
    Ronald P Dematteo
    Hepatobiliary Service, Memorial Sloan-Kettering Cancer Center, New York, New York, USA
    Curr Probl Surg 40:144-93. 2003
  28. ncbi Mechanisms of sunitinib resistance in gastrointestinal stromal tumors harboring KITAY502-3ins mutation: an in vitro mutagenesis screen for drug resistance
    Tianhua Guo
    Departments of Pathology, Medicine, and Surgery, Memorial Sloan Kettering Cancer Center, Sloan Kettering Institute, New York, NY 10021, USA
    Clin Cancer Res 15:6862-70. 2009
    ..The clinical benefit of sunitinib is genotype-dependent in regards to both primary and secondary mutations, with GIST patients harboring the KIT(AY502-3ins) exon 9 mutation being the most sensitive...
  29. ncbi Sorafenib inhibits the imatinib-resistant KITT670I gatekeeper mutation in gastrointestinal stromal tumor
    Tianhua Guo
    Department of Pathology, Memorial Sloan Kettering Cancer Center, NY 10021, USA
    Clin Cancer Res 13:4874-81. 2007
    ....
  30. ncbi Molecular characterization of pediatric gastrointestinal stromal tumors
    Narasimhan P Agaram
    Department of Pathology, Sloan Kettering Institute, New York, New York 10021, USA
    Clin Cancer Res 14:3204-15. 2008
    ....
  31. ncbi Rates and patterns of recurrence for percutaneous radiofrequency ablation and open wedge resection for solitary colorectal liver metastasis
    R R White
    Department of Surgical Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Gastrointest Surg 11:256-63. 2007
    ..The purpose of this study was to compare rates and patterns of disease progression following percutaneous, image-guided radiofrequency ablation (RFA) and nonanatomic wedge resection for solitary colorectal liver metastases...
  32. ncbi Gallbladder cancer (GBC): 10-year experience at Memorial Sloan-Kettering Cancer Centre (MSKCC)
    A Duffy
    Department of Medicine, Memorial Sloan Kettering Cancer Center MSKCC, New York, NY 10021, USA
    J Surg Oncol 98:485-9. 2008
    ..The incidence of gallbladder cancer (GBC) in the US is 1.2/100,000. This report examines the patterns of presentation, adjuvant treatment and survival of a large cohort of patients with GBC evaluated at MSKCC over a 10-year period...
  33. ncbi Effect of postoperative morbidity on long-term survival after hepatic resection for metastatic colorectal cancer
    Hiromichi Ito
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Ann Surg 247:994-1002. 2008
    ..The objective of this study was to evaluate the impact of postoperative morbidity on the long-term outcome after liver resection for MCRC...
  34. ncbi Synchronous hepatic metastases from colon cancer: changing treatment strategies and results of surgical intervention
    Bridget N Fahy
    Department of Surgery, The Methodist Hospital, Houston, TX 77030, USA
    Ann Surg Oncol 16:361-70. 2009
    ..A multidisciplinary treatment approach which combines both medical and surgical modalities may be associated with improved survival...
  35. ncbi Diabetes is associated with increased perioperative mortality but equivalent long-term outcome after hepatic resection for colorectal cancer
    Sarah A Little
    Department of Surgery, Hepatobiliary Service, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
    J Gastrointest Surg 6:88-94. 2002
    ..We conclude that the presence of diabetes is associated with a higher incidence of perioperative mortality. In patients with diabetes mellitus and parenchymal steatosis, major hepatic resection should be undertaken with caution...
  36. ncbi Role of intraoperative thermoablation combined with resection in the treatment of hepatic metastasis from colorectal cancer
    Peter Kornprat
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Arch Surg 142:1087-92. 2007
    ..Thermoablation, either cryosurgical ablation (CSA) or radiofrequency ablation (RFA), combined with resection is effective in the treatment of extensive bilobar colorectal metastasis...
  37. ncbi Predictors and patterns of recurrence after resection of hepatocellular carcinoma
    Charles Cha
    Hepatobiliary Service, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
    J Am Coll Surg 197:753-8. 2003
    ..The current study underscores the need for effective adjuvant therapy for patients with HCC treated with partial hepatectomy...
  38. ncbi Peritoneal washings are not predictive of occult peritoneal disease in patients with hilar cholangiocarcinoma
    R C Martin
    Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
    J Am Coll Surg 193:620-5. 2001
    ..There was no association between percutaneous transhepatic biliary drainage and peritoneal tumor seeding...
  39. ncbi Gastrointestinal stromal tumors and leiomyosarcoma of the abdomen and retroperitoneum: a clinical comparison
    B M Clary
    Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA
    Ann Surg Oncol 8:290-9. 2001
    ..The pattern of distant spread follows the known patterns of hematogenous dissemination. Complete surgical resection is the cornerstone of treatment for primary GIST and LMS and in selected patients with local and distant recurrence...
  40. ncbi The role of staging laparoscopy in hepatobiliary malignancy: prospective analysis of 401 cases
    Y Fong
    Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA
    Ann Surg Oncol 10:183-9. 2003
    ..Targeting laparoscopy to patients at high risk for unresectable disease requires consideration of disease-specific factors; however, the surgeons' preoperative impression of resectability is also important...
  41. ncbi Influence of transfusions on perioperative and long-term outcome in patients following hepatic resection for colorectal metastases
    David A Kooby
    Department of Surgery, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Ann Surg 237:860-9; discussion 869-70. 2003
    ..Blood conservation methods should be used to avoid transfusion, especially in patents currently requiring limited amounts of transfused blood products...
  42. ncbi Preoperative CA 19-9 and the yield of staging laparoscopy in patients with radiographically resectable pancreatic adenocarcinoma
    Shishir K Maithel
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Ann Surg Oncol 15:3512-20. 2008
    ..Factors associated with the likelihood of subradiographic unresectable disease have not been clearly defined...
  43. ncbi Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resection
    Itaru Endo
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Ann Surg 248:84-96. 2008
    ..This study analyzes changes in IHC frequency, demographics, and treatment outcome in a consecutive and single institutional cohort...
  44. ncbi A novel prognostic nomogram is more accurate than conventional staging systems for predicting survival after resection of hepatocellular carcinoma
    Clifford S Cho
    Hepatobiliary Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Am Coll Surg 206:281-91. 2008
    ..Numerous staging systems have been devised for purposes of risk classification; we sought to identify the optimal staging system to predict postoperative survival...
  45. ncbi Comparative ultrastructural analysis and KIT/PDGFRA genotype in 125 gastrointestinal stromal tumors
    Narasimhan P Agaram
    Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA
    Ultrastruct Pathol 30:443-52. 2006
    ..GISTs showing both NS-G and microtubules were associated with KIT exon 11 genotype and spindle cell morphology. PDGFRA mutated cases were associated with gastric location, predominantly epithelioid morphology and lacked NS-G...
  46. ncbi Surgical therapy for metastatic disease to the liver
    David J Bentrem
    Hepatobiliary Service, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA
    Annu Rev Med 56:139-56. 2005
    ..The indications for surgical treatment of liver metastases are broadening as a variety of novel therapies are being developed, including hepatic artery embolization, hepatic artery infusion of chemotherapy, and radiofrequency ablation...
  47. ncbi Gastrointestinal stromal tumor: 5 years later
    Sanne M van der Zwan
    Hepatobiliary Service, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA
    Cancer 104:1781-8. 2005
    ..The integration of surgery and molecular therapy in GIST will serve as a prototype for the management of other solid tumors for which targeted agents become available...
  48. ncbi Adequate lymph node assessment for extrahepatic bile duct adenocarcinoma
    Kaori Ito
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Ann Surg 251:675-81. 2010
    ..To examine the importance of adequate lymph node sampling in staging of extrahepatic bile duct cancer (EHBDCA)...
  49. ncbi Increased use of parenchymal-sparing surgery for bilateral liver metastases from colorectal cancer is associated with improved mortality without change in oncologic outcome: trends in treatment over time in 440 patients
    Jason S Gold
    Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Ann Surg 247:109-17. 2008
    ..We aimed to assess the evolution of the technical approach over time and correlations with morbidity, mortality, and oncologic outcome...
  50. ncbi Outcome of partial hepatectomy for large (> 10 cm) hepatocellular carcinoma
    Kui-Hin Liau
    Hepatobiliary Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA
    Cancer 104:1948-55. 2005
    ..Minimizing intraoperative blood loss appears to be critical for favorable long-term outcome in patients with large HCC...
  51. ncbi Malignant progression in IPMN: a cohort analysis of patients initially selected for resection or observation
    J LaFemina
    Department of Surgical Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Ann Surg Oncol 20:440-7. 2013
    ..The relative risk of carcinoma in regions remote from the radiographically identified cyst remains poorly defined. This study describes the natural history of IPMN in patients initially selected for resection or surveillance...
  52. ncbi Management of 155 patients with benign liver tumours
    C K Charny
    Department of Surgery, New York Presbyterian Hospital-Cornell Campus, New York, NY, USA
    Br J Surg 88:808-13. 2001
    ..Symptomatic patients with a small FNH or haemangioma can be observed because their symptoms are unlikely to be related to the liver tumour. Percutaneous needle biopsy rarely changes management...
  53. ncbi Randomized phase II trial of adjuvant hepatic arterial infusion and systemic chemotherapy with or without bevacizumab in patients with resected hepatic metastases from colorectal cancer
    Nancy E Kemeny
    Memorial Sloan Kettering Cancer Center, Weill Medical College, NY, USA
    J Clin Oncol 29:884-9. 2011
    ..Add systemic bevacizumab (Bev) to adjuvant hepatic arterial infusion (HAI) plus systemic therapy after liver resection to increase recurrence-free survival (RFS)...
  54. ncbi Surgery and ablative therapy for hepatocellular carcinoma
    Charles Cha
    Hepatobiliary Service, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA
    J Clin Gastroenterol 35:S130-7. 2002
    ..The rational application of the myriad of therapies to a patient with HCC is designed to maximize both quality of life and survival...
  55. ncbi Autologous versus allogeneic transfusions: no difference in perioperative outcome after partial hepatectomy. Autologous transfusion on hepatectomy outcome
    James O Park
    Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, C897, New York, NY 10021, USA
    J Gastrointest Surg 11:1286-93. 2007
    ..In patients undergoing hepatic resection, autologous blood transfusion did not demonstrably improve perioperative outcome when compared to a matched cohort of patients receiving a similar number of allogeneic units...
  56. ncbi Natural history of patients with subcentimeter pulmonary nodules undergoing hepatic resection for metastatic colorectal cancer
    Shishir K Maithel
    Department of Surgery, Division of Surgical Oncology, Emory University, Atlanta, GA, USA
    J Am Coll Surg 210:31-8. 2010
    ..CT imaging frequently detects subcentimeter pulmonary nodules (SPN) in patients undergoing resection of colorectal cancer liver metastases. Their clinical significance is unknown...
  57. ncbi A prospective randomized trial of acute normovolemic hemodilution compared to standard intraoperative management in patients undergoing major hepatic resection
    William R Jarnagin
    Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, C 887, New York, NY 10065, USA
    Ann Surg 248:360-9. 2008
    ....
  58. ncbi Effect on outcome of recurrence patterns after hepatectomy for colorectal metastases
    Michael D'Angelica
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Ann Surg Oncol 18:1096-103. 2011
    ..Despite improvements in surgery and chemotherapy, most patients develop recurrence after hepatectomy for metastatic colorectal cancer. Data are lacking on the effect of these patterns on outcome...
  59. ncbi Histopathologic and immunohistochemical features of tissue adherent to multitined electrodes after RF ablation of liver malignancies can help predict local tumor progression: initial results
    Constantinos T Sofocleous
    Section of Interventional Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, Room H 118, New York, NY 10065, USA
    Radiology 249:364-74. 2008
    ..To determine whether histopathologic and immunohistochemical features of tissue adherent to electrodes after radiofrequency (RF) ablation of liver malignancies can help predict local tumor progression (LTP)...
  60. ncbi Survival after hepatic resection for metastatic colorectal cancer: trends in outcomes for 1,600 patients during two decades at a single institution
    Michael G House
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Am Coll Surg 210:744-52, 752-5. 2010
    ..This study analyzes factors associated with differences in long-term outcomes after hepatic resection for metastatic colorectal cancer over time...
  61. ncbi Analysis of the extent of resection for adenocarcinoma of the gallbladder
    Michael D'Angelica
    Hepatobiliary Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Ann Surg Oncol 16:806-16. 2009
    ..Major hepatic resections, including major hepatectomy and CBD excision, are appropriate when necessary to clear disease but are not mandatory in all cases...
  62. ncbi Combined hepatocellular and cholangiocarcinoma: demographic, clinical, and prognostic factors
    William R Jarnagin
    Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Cancer 94:2040-6. 2002
    ....
  63. ncbi Multidisciplinary treatment of gastrointestinal stromal tumors
    T Peter Kingham
    Department of Surgery, Memorial Sloan Kettering Cancer Center, 303 E 60th Street, Apt 28E, NY, NY 10022, USA
    Surg Clin North Am 89:217-33, x. 2009
    ..Diagnosing and treating GIST requires a multidisciplinary approach, given the combination of pathologic and radiographic evaluation, surgical treatment, and oncologic care required to successfully treat patients with GIST...
  64. ncbi Predicting the risk of perioperative transfusion for patients undergoing elective hepatectomy
    Camelia S Sima
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Ann Surg 250:914-21. 2009
    ..To develop 2 instruments that predict the probability of perioperative red blood cell transfusion in patients undergoing elective liver resection for primary and secondary tumors...
  65. ncbi Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial
    Ronald P Dematteo
    Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Lancet 373:1097-104. 2009
    ..We postulated that adjuvant treatment with imatinib would improve recurrence-free survival compared with placebo after resection of localised, primary gastrointestinal stromal tumour...
  66. ncbi Gene expression in gastrointestinal stromal tumors is distinguished by KIT genotype and anatomic site
    Cristina R Antonescu
    Departments of Pathology, Memorial Sloan Kettering Cancer Center, and Molecular Biology, Computational Biology Center, Sloan Kettering Institute, New York, New York 10021, USA
    Clin Cancer Res 10:3282-90. 2004
    ..We tested the hypothesis that the gene expression profile in GISTs might be related to KIT genotype and possibly to other clinicopathological factors...
  67. ncbi Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation
    Cristina R Antonescu
    Department of Pathology, Sloan Kettering Institute, New York, New York, USA
    Clin Cancer Res 11:4182-90. 2005
    ..That acquired resistance to imatinib in GIST commonly occurs via secondary gene mutation in the KIT kinase domain has implications for strategies to delay or prevent imatinib resistance and to employ newer targeted therapies...
  68. ncbi Hepatic follicular dendritic cell sarcoma without Epstein-Barr virus expression
    Ulises Torres
    Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
    Arch Pathol Lab Med 129:1480-3. 2005
    ..Based on our experience and a review of the published reports, we summarize the clinical and pathologic features of hepatic follicular dendritic cell sarcoma and its surgical management...
  69. ncbi Profile of plasma angiogenic factors before and after hepatectomy for colorectal cancer liver metastases
    Sam S Yoon
    Department of Surgery, Division of Surgical Oncology, Massachusetts General Hospital, Harvard Medical School, Yawkey 7B 7926, 55 Fruit Street, Boston, Massachusetts 02114, USA
    Ann Surg Oncol 13:353-62. 2006
    ..Circulating angiogenic factors in patients with colorectal cancer liver metastases may promote tumor growth and contribute to liver regeneration after partial hepatectomy...
  70. ncbi Differential cell cycle-regulatory protein expression in biliary tract adenocarcinoma: correlation with anatomic site, pathologic variables, and clinical outcome
    William R Jarnagin
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 24:1152-60. 2006
    ..This clinicopathologic study characterizes differences in cell cycle-regulatory protein expression across the spectrum of BTA...
  71. ncbi Lack of evidence for increased operative morbidity after hepatectomy with perioperative use of bevacizumab: a matched case-control study
    Michael D'Angelica
    Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, New York 10021, USA
    Ann Surg Oncol 14:759-65. 2007
    ..Perioperative bev is now commonly used in patients undergoing hepatic resection. Little is known, however, about the safety of perioperative bev use in the setting of hepatic resection...
  72. ncbi Papillary phenotype confers improved survival after resection of hilar cholangiocarcinoma
    William R Jarnagin
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Ann Surg 241:703-12; discussion 712-4. 2005
    ..The current study compares outcome after resection of papillary hilar cholangiocarcinoma to that of the more common nodular-sclerosing subtype...
  73. ncbi Impact of steatosis on perioperative outcome following hepatic resection
    David A Kooby
    Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA
    J Gastrointest Surg 7:1034-44. 2003
    ..Steatosis alone should not preclude aggressive hepatic resection for neoplasms when indicated; however, patients with marked steatosis undergoing large resections should still be approached with due caution...
  74. ncbi The impact of margins on outcome after hepatic resection for colorectal metastasis
    Chandrakanth Are
    Hepatobiliary Division, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Ann Surg 246:295-300. 2007
    ..To analyze the impact of margin width on long-term outcome after hepatic resection for colorectal metastasis...
  75. ncbi Association of KIT exon 9 mutations with nongastric primary site and aggressive behavior: KIT mutation analysis and clinical correlates of 120 gastrointestinal stromal tumors
    Cristina R Antonescu
    Department of Pathology, Memorial Sloan Kettering Cancer Center, and Molecular Biology Program, Sloan Kettering Institute, New York, New York, 10021, USA
    Clin Cancer Res 9:3329-37. 2003
    ..The impact of KIT mutation in other regions, such as the extracellular or kinase domains, is not well-defined and fewer than 30 cases have been published to date...
  76. ncbi Resection of hepatocellular carcinoma in patients otherwise eligible for transplantation
    Charles H Cha
    Hepatobiliary Service, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Ann Surg 238:315-21; discussion 321-3. 2003
    ..Resection should be considered the standard therapy for patients with HCC who have adequate liver reserve...
  77. ncbi Actual 10-year survival after resection of colorectal liver metastases defines cure
    James S Tomlinson
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 25:4575-80. 2007
    ..There is now sufficient follow-up on a significant number of patients to address the curative intent of resecting CLM...
  78. ncbi Segment-oriented approach to liver resection
    K H Liau
    Hepatobiliary Service, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Surg Clin North Am 84:543-61. 2004
    ..The technique promotes tumor clearance while con-serving uninvolved parenchyma...
  79. ncbi Neutrophil IL-10 suppresses peritoneal inflammatory monocytes during polymicrobial sepsis
    Lee M Ocuin
    Hepatopancreatobiliary Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    J Leukoc Biol 89:423-32. 2011
    ..In vitro experiments confirmed that monocyte suppression was mediated by neutrophil-derived IL-10. Thus, during septic peritonitis, neutrophils suppress peritoneal inflammatory monocytes through IL-10 and are dispensable for survival...
  80. ncbi Histologic grade is correlated with outcome after resection of hepatic neuroendocrine neoplasms
    Clifford S Cho
    Section of Surgical Oncology, University of Wisconsin School of Medicine and Public Health, H4 724 Clinical Sciences Center, 600 Highland Avenue, Madison, WI 53792 7375, USA
    Cancer 113:126-34. 2008
    ..Consequently, guidelines for treatment remain unclear. Current pathologic classification systems do not permit meaningful discrimination of hepatic neuroendocrine neoplasms...
  81. ncbi Perihepatic lymph node micrometastases impact outcome after partial hepatectomy for colorectal metastases
    Joseph J Bennett
    Division of Hepatobiliary Surgery, Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Ann Surg Oncol 15:1130-6. 2008
    ..This study uses standard pathologic analysis and immunohistochemistry (IHC) to determine the impact of occult metastatic disease to perihepatic LN in patients with colorectal cancer undergoing hepatectomy...
  82. ncbi Molecular mechanisms in hepatocellular carcinoma development
    Charles Cha
    Department of Surgery, Yale University School of Medicine, New Haven, CT, USA
    Best Pract Res Clin Gastroenterol 19:25-37. 2005
    ..It is not clear which events are critical in tumor initiation versus tumor progression. RNA expression arrays and proteomics hold promise to provide further clues about this common and complex cancer...
  83. ncbi Volumetric analysis predicts hepatic dysfunction in patients undergoing major liver resection
    Margo Shoup
    Departments of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
    J Gastrointest Surg 7:325-30. 2003
    ..Preoperative assessment of future liver volume remaining distinguishes which patients undergoing liver resection will most likely benefit from preoperative liver enhancement techniques such as portal vein embolization...
  84. ncbi The use of fresh frozen plasma after major hepatic resection for colorectal metastasis: is there a standard for transfusion?
    Robert C G Martin
    Hepatobiliary Service, Memorial Sloan Kettering Cancer Center, Department of Surgery, New York, NY 10021, USA
    J Am Coll Surg 196:402-9. 2003
    ..Transfusion of fresh frozen plasma (FFP) might be required after major hepatectomy because of blood loss or coagulopathy, but there are no standard criteria for the use of FFP in this setting...
  85. ncbi Diagnostic laparoscopy prior to planned hepatic resection for colorectal metastases
    Stephen R Grobmyer
    Department of Surgery, Division of Hepatobiliary Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Arch Surg 139:1326-30. 2004
    ..The yield of laparoscopy increases with increasing CRS. Preventing celiotomy with laparoscopy is associated with a decreased length of hospital stay and earlier initiation of postoperative chemotherapy...
  86. ncbi Surgical therapy for hepatocellular carcinoma
    Charles Cha
    Gastrointestinal and Oncologic Surgery, Yale University School of Medicine, New Haven, Connecticut, USA
    Adv Surg 38:363-76. 2004
  87. ncbi Patterns of initial disease recurrence after resection of gallbladder carcinoma and hilar cholangiocarcinoma: implications for adjuvant therapeutic strategies
    William R Jarnagin
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 98:1689-700. 2003
    ....
  88. ncbi Outcome of patients with fibrolamellar hepatocellular carcinoma
    Francesco Stipa
    Department of Surgery, San Giovanni Hospital, Rome, Italy
    Cancer 106:1331-8. 2006
    ..These tumors have a relatively indolent tumor biology, and late recurrences are common. Repeat resections for recurrence should be considered given the lack of other effective treatment options...
  89. ncbi Natural killer cell depletion confounds the antitumor mechanism of endogenous IL-12 overexpression
    George Miller
    Hepatobiliary Service, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
    Int J Cancer 110:395-402. 2004
    ..These data have critical implications for investigating the immunologic mechanisms of experimental models that utilize gene transfer...
  90. ncbi Staging laparoscopy in patients with extrahepatic biliary carcinoma. Analysis of 100 patients
    Sharon M Weber
    Department of Surgery, Hepatobiliary Service, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA
    Ann Surg 235:392-9. 2002
    ..All patients with potentially resectable primary gallbladder cancer and patients with T2/T3 hilar cholangiocarcinoma should undergo staging laparoscopy before surgical exploration...
  91. ncbi Improvement in perioperative outcome after hepatic resection: analysis of 1,803 consecutive cases over the past decade
    William R Jarnagin
    Departments of Surgery and Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Ann Surg 236:397-406; discussion 406-7. 2002
    ..To assess the nature of changes in the field of hepatic resectional surgery and their impact on perioperative outcome...
  92. ncbi Outcomes after resection of synchronous or metachronous hepatic and pulmonary colorectal metastases
    George Miller
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Am Coll Surg 205:231-8. 2007
    ..But the benefits of resection and appropriate selection criteria in patients who develop both hepatic and pulmonary metastases are ill defined...
  93. ncbi Neoadjuvant therapy for gastrointestinal stromal tumor (GIST): racing against resistance
    Jason S Gold
    Ann Surg Oncol 14:1247-8. 2007

Research Grants13

  1. STI571 Therapy for Gastrointestinal Stromal Tumors
    Ronald DeMatteo; Fiscal Year: 2002
    ..The results are essential to advance our understanding of GIST biology and determine the therapeutic value and limitations of STI571. ..
  2. Liver Dendritic Cells in Tolerance and Immunity
    Ronald DeMatteo; Fiscal Year: 2007
    ..We expect the findings to be important for immunologic conditions of the liver that include autoimmunity, infection, transplantation, and cancer. ..
  3. Molecular Mechanisms in Gastrointestinal Stromal Tumor
    Ronald DeMatteo; Fiscal Year: 2007
    ..The results will further define GIST biology and be applicable to other diseases treated with molecular agents. ..
  4. Natural Killer Dendritic Cells in Listeria Infection
    Ronald DeMatteo; Fiscal Year: 2007
    ....
  5. Liver Dendritic Cells in Tolerance and Immunity
    Ronald P Dematteo; Fiscal Year: 2010
    ..Our investigations will be useful in identifying new therapies to treat ischemia reperfusion injury that occurs in humans. ..